Nephropathy of type-2 diabetes mellitus

Journal of the American Society of Nephrology

Volumn 9, Issue 11, 1998, Pages 2157-2169

  Ruggenenti, Piero ^a,b   Remuzzi, Giuseppe ^a  

^a OSPEDALI RIUNITI   (Italy)

^b MARIO NEGRI INST PHARMACOL RES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ARTICLE; BRADYCARDIA; COST EFFECTIVENESS ANALYSIS; DIABETIC NEPHROPATHY; DRUG INDICATION; EARLY DIAGNOSIS; GLOMERULUS FILTRATION RATE; HEART FAILURE; HUMAN; HYPERTENSION; HYPERURICEMIA; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK FACTOR;

EID: 0031728527     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (86)

1. Striker GE, Agodoa LL, Held P, Doi T, Conti F, Striker L: Kidney disease of diabetes mellitus (diabetic nephropathy): Perspectives in the United States. J Diabetes Complications 5: 51-52, 1991
2. United States Renal Data System: USRDS 1994 annual data report. Bethesda, MD. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1994
3. United States Renal Data System: USRDS 1997 annual data report. Bethesda, MD, National Institute of Diabetes and Digestive and Kidney Diseases, 1997
4. Pastan S, Bailey J: Dialysis therapy. N Engl J Med 338: 1428-1437, 1998
5. Mogensen CE, Keane WF, Bennett PH, Jerums G, Parving H-H, Passa P, Steffes MW, Striker GE, Viberti GC: Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 346: 1080-1084, 1995
6. Consensus Statement: Diagnosis and management of nephropathy in patients with diabetes mellitus. Diabetes Care 19: 103-106, 1996
7. Delcourt C, Villatte-Cathelineau B, Vauzzelle-Kervroedan F, Papoz L: The Codia-Inserm Zeneca Pharma Study Group: Clinical correlates of advanced retinopathy in type II diabetic patients: Implications for screening. J Clin Epidemiol 49: 679-685, 1996
8. Parving H-H, Osterby R, Anderson PW, Hsueh WA: Diabetic nephropathy. In: Brenner's & Rector's The Kidney, Vol. 2, edited by Brenner BM. 5th Ed., Philadelphia, W. B. Saunders, 1996, pp 1864-1892
9. Ruggenenti P, Remuzzi G: The diagnosis of renal involvement in non-insulin-dependent diabetes mellitus. Curr Opin Nephrol Hypertens 6: 141-145, 1997
10. Pettitt D, Saad M, Bennett PH, Nelson RG, Knowler WC: Familial predisposition to renal disease in two generations of Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 33: 438-443, 1990
11. Faronato PP, Maioli M, Tonoli G, Brocco E, Noventa F, Piarulli F, Abaterusso C, Modena F, de Bigontina G, Velussi M, Inchiostro S, Santeusanio F, Bueti A, Nosadini R, for the Italian NIDDM Nephropathy Study Group: Clustering of albumin excretion rate abnormalities in Caucasian patients with NIDDM. Diabetologia 40: 816-823, 1997
12. Gall M-A, Hougaard P, Borch-Johnsen K, Parving H-H: Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: Prospective, observational study. Br Med J 314: 783-788, 1997
13. Nelson RG, Knowler WC, Pettitt DJ: Incidence and determinants of elevated urinary albumin excretion in Pima Indians with NIDDM. Diabetes Care 18: 182-187, 1995
14. Myers BD, Nelson RG, Williams GW: Glomerular function in Pima Indians with noninsulin-dependent diabetes mellitus of recent onset. J Clin Invest 88: 524-530, 1991
15. Nelson RG, Bennett PH, Beck GJ, for the Diabetic Renal Disease Study Group: Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. N Engl J Med 335: 1636-1642, 1996
16. Remuzzi G, Ruggenenti P, Benigni A: Understanding the nature of renal disease progression. Kidney Int 51: 2-15, 1997
17. Deckert T, Kofoed-Enevoldsen A, Vidai P: Size and charge selectivity of glomerular filtration in type 1 (insulin-dependent) diabetic patients with and without albuminuria. Diabetologia 36: 244-251, 1993
18. Nelson RG, Meyer TW, Myers BD, Bennett PH: Clinical and pathological course of renal disease in non-insulin-dependent diabetes mellitus: The Pima Indian experience. Semin Nephrol 17: 124-131, 1997
19. Feldt-Rasmussen B: Microalbuminuria and clinical nephropathy in type I (insulin-dependent) diabetes mellitus: Pathophysiological mechanisms and intervention studies. Dan Med Bull 36: 405-415, 1989
20. Fioretto P, Mauer M, Brocco E, Velussi M, Frigato F, Muollo B, Sambataro M, Abaterusso C, Baggio B, Crepaldi G, Nosadini R: Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 39: 1569-1576, 1996
21. Velussi M, Brocco E, Frigato F, Zolli M, Muollo B, Maioli M, Carraro A, Tonolo G, Fresu P, Cernigoi AM, Fioretto P, Nosadini R: Effects of Cilazapril and Amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 45: 216-222, 1996
22. Ruggenenti P, Mosconi L, Bianchi L, Cortesi L, Campana M, Pagani G, Mecca G, Remuzzi G: Long-term treatment with either enalapril or nitrendipine stabilizes albuminuria and increases glomerular filtration rate in non-insulin-dependent diabetic patients. Am J Kidney Dis 24: 753-761, 1994
23. Iordache BE, Mohamed EI, Zatelli N, Remuzzi G, Remuzzi A: Hydraulic permeability of glomerular membrane is decreased in patients with type II diabetes and microalbuminuria [Abstract]. J Am Soc Nephrol 6: 450, 1995
24. Bertani T, Iordache BE, Foglieni C, Gambara V, Mohamed EI, Remuzzi A: Morphometrical analysis of glomerular structure in patiens with type II diabetes and microalbuminuria [Abstract]. J Am Soc Nephrol 4: 789, 1993
25. Myers BD, Winetz JA, Chui F, Michaels AS: Mechanisms of proteinuria in diabetic nephropathy: A study of glomerular barrier function. Kidney Int 21: 633-641, 1982
26. Remuzzi A, Ruggenenti P, Mosconi L, Pata V, Viberti G, Remuzzi G: Effect of low-dose enalapril on glomerular size-selectivity in human diabetic nephropathy. J Nephrol 6: 36-43, 1993
27. Remuzzi A, Perticucci E, Ruggenenti P, Mosconi L, Limonta M, Remuzzi G: Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy. Kidney Int 39: 1267-1273, 1991
28. Myers BD, Nelson RG, Tan M, Beck GJ, Bennett PH, Knowler WC, Blouch K, Mitch WE: Progression of overt nephropathy in non-insulin-dependent diabetes. Kidney Int 47: 1781-1789, 1995
29. Olsen S, Mogensen CE: How often is NIDDM complicated with non-diabetic renal diisease? An analysis of renal biopsies and the literature. Diabetologia 39: 1638-1645, 1996
30. Bertani T, Gambara V, Remuzzi G: Structural basis of diabetic nephropathy in microalbuminuric NIDDM patients: A light microscopy study. Diabetologia 39: 1625-1628, 1996
31. Ellis EN, Steffess MW, Chavers BM, Mauer SM: Observation of glomerular epithelial cell structure in patients with type I diabetes mellitus. Kidney Int 32: 736-741, 1987
32. Gambara V, Mecca G, Remuzzi G, Bertani T: Heterogeneous nature of renal lesions in type II diabetes. J Am Soc Nephrol 3: 1458-1466, 1993
33. Parving H-H, Gall M-A, Skott P, Jorghensen HE, Lokkegaard H, Jorgens F, Nielsen B, Larsen S: Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. Kidney Int 41: 758-762, 1992
34. Bader R, Bader H, Grund K, Mackensen-Hahn S, Christ H, Bohle A: Structure and function of the kidney in diabetic glomerulosclerosis: Correlations between morphological ad functional parameters. Pathol Res Pract 167: 204-216, 1980
35. Waldherr R, Ilkenhans C, Ritz E: How frequent is glomerulonephritis in diabetes mellitus type II? Clin Nephrol 37: 271-273, 1992
36. Pagtalunan ME, Miller PL, Jumping-Eagle S: Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 99: 342-348, 1997
37. Mogensen CE: Microalbuminuria predicts clinical proteinuria arid early mortality in maturity-onset diabetes. N Engl J Med 310: 356-360, 1984
38. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M: Long term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 118: 577-581, 1993
39. Parving H-H: Initiation and progression of diabetic nephropathy. N Engl J Med 335: 1682-1683, 1996
40. Mosconi L, Ruggenenti P, Perna A, Mecca G, Remuzzi G: Nitrendipine and enalapril improve albuminuria and glomerular filtration rate in non-insulin dependent diabetes. Kidney Int 49[Suppl 55]: S91-S93, 1996
41. Schmitz A, Vaeth M: Microalbuminuria: A major risk factor in non-insulin-dependent diabetes. A 10-year follow-up study of 503 patients. Diabetic Med 5: 126-134, 1988
42. Striker GE: Report on a workshop zo develop management recommendations for the prevention of progression in chronic renal disease (Bethesda, April 1994). Nephrol Dial Transplant 10: 290-292, 1995
43. Deckert T: Nephropathy and coronary death: The fatal twins in diabetes mellitus. Nephrol Dial Transplant 9: 1069-1071, 1994
44. Nielsen FS, Rossing P, Bang L, Smidt UM, Svendsen TL, Gall MA, Parving H-H: Endothelial dysfunction in NIDDM patients with and without nephropathy [Abstract]. J Am Soc Nephrol 5: 380, 1994
45. Parving H-H: Renoprotection in diabetes: Genetic and non-genetic risk factors and treatment. Diabetologia 41: 745-759, 1998
46. Rigat B, Hubert C, Corvol P, Soubrier F: PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl-carboxy peptidose 1). Nucleic Acids Res 20: 1433, 1992
47. Yoshida H, Kuriyama S, Atsumi Y: Angiotensin I converting enzyme gene polymorphism in non-insulin-dependent diabetes mellitus. Kidney Int 50: 657-664, 1996
48. Fujisawa T, Ikegami H, Kawaguchi Y, Hamada Y, Ueda H, Shintani M, Fukuda M, Ogihara T: Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia 41: 47-53, 1998
49. Nielsen S, Schmitz O, Moller N: Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 36: 1079-1086, 1993
50. Orth SR, Ritz E, Schrier RW: The renal risk of smoking. Kidney Int 51: 1669-1677, 1997
51. Sawicki PT, Didjurgeit U, Muhllauser I, Bender R, Heinemann L, Berger M: Smoking is associated with progression of diabetic nephropathy. Diabetes Care 17: 126-131, 1994
52. Hansen HP, Rossing P, Jacobsen P, Jensen BR, Parving H-H: The acute effect of smoking on systemic haemodynamics, kidney and endothelial function in insulin-dependent diabetic patients with microalbuminuria. Scand J Clin Lab Invest 56: 393-399, 1996
53. Ruggenenti P, Gambara V, Perna A, Bertani T, Remuzzi G: The nephropathy of non-insulin dependent diabetes: Predictors of outcome relative to diverse patterns of renal injury. J Am Soc Nephrol 1998, in press
54. The GISEN Group: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349: 1857-1863, 1997
55. Yokoyama H, Tomonaga O, Hirayama M, Ishii A, Takeda M, Babazono T, Ujihara U, Takahashi C, Omori Y: Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients. Diabetologia 40: 405-411, 1997
56. Ruggenenti P, Remuzzi G: Anti-hypertensive agents and incipient diabetic nephropathy. In: The Diabetes Annual/9, edited by Marshall SM, Home PD, Rizza RA, Amsterdam, Elsevier, 1995, pp 295-317
57. Ruggenenti P, Remuzzi G: The renoprotective action of angiotensin-converting enzyme inhibitors in diabetes. Exp Nephrol 4: 53-60, 1996
58. Agardh CD, Garcia PJ, Charbonnel B, Angelkort B, Barnett AH: Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens 10: 185-192, 1996
59. Lebovitz HE, Wiegmann TB, Cnaan A, Shahinfar S, Sica DA, Broadstone V, Schwartz SL, Mengel MC, Segal R: Renal protective effects of enalapril in hypertensive NIDDM: Role of baseline albuminuria. Kidney Int Suppl 45: S150-S155, 1994
60. Trevisan R, Tiengo A: Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin dependent diabetic patients. Am J Hypertens 8: 876-883, 1995
61. Kasiske BL, Kalil RSN, Ma JZ, Liao M, Keane WF: Effects of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis. Ann Intern Med 118: 129-138, 1993
62. Sano T, Kawamura T, Matsumae H: Effects of long-term enalapril treatment on persistent micro-albuminuria in well-controlled hypertensive and normotensive NIDDM patients. Diabetes Care 17: 420-424, 1994
63. Wu M, Yu C, Yang C-W: Poor pre-dialysis glycaemic control is a predictor of mortality in type II diabetic patients on maintenance haemodialysis. Nephrol Dial Transplant 12: 2105-2110, 1997
64. Morelli E, Loon N, Meyer TW, Peters W, Myers BD: Effects of converting-enzyme inhibition on barrier function in diabetic glomerulopathy. Diabetes 39: 76-82, 1990
65. Ruggenenti P, Remuzzi G: Angiotensin-converting enzyme inhibitor therapy for non-diabetic progressive renal disease. Curr Opin Nephrol Hypertens 6: 489-495, 1997
66. Mosconi L, Remuzzi A, Ruggenenti P, Sangalli F, Gambara V, Remuzzi G: Glomerular size-selective dysfunction in type-2 diabetes with glomerulopathy is not ameliorated by ACE inhibition and calcium channel blockade [Abstract]. J Am Soc Nephrol 7: 1362, 1996
67. Nielsen FS, Rossing P, Gall MA, Skott P, Smidt UM, Parving H-H: Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 46: 1182-1188, 1997
68. Bjorck S, Mulec H, Johnsen SA, Nordén G, Aurell M: Renal protective effect of enalapril in diabetic nephropathy. Br Med J 304: 339-343, 1992
69. Parving H-H, Rossing P: The use of antihypertensive agents in prevention and treatment of diabetic nephropathy. Curr Opin Nephrol Hypertens 3: 292-300, 1994
70. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL, for the Modification of Diet in Renal Disease (MDRD) Study Group: Blood pressure control, proteinuria, and the progression of renal disease: The modification of diet in renal disease study. Ann Intern Med 123: 754-762, 1995
71. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S, for the HOT Study Group: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 351: 1755-1762, 1998
72. Estacio RO, Jeffers BW, Hiatt WR: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338: 645-652, 1998
73. Tatti P, Pahor M, Byington RP: Outcome results of the Fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and non-insulin dependent diabetes mellitus. Diabetes Care 21: 597-603, 1998
74. Bakris G: Combination therapy for hypertension and renal disease in diabetics as compared to non diabetics. In: The Kidney and Hypertension in Diabetes Mellitus, edited by Mogensen CE, 3rd Ed., Norwell, MA, Kluwer, 1997, pp 561-568
75. Siegel JE, Krolewski AS, Warram JH, Weinstein MC: Cost-effectiveness of screening and early treatment of nephropathy in patients with insulin-dependent diabetes mellitus. J Am Soc Nephrol 3[Suppl 1]: S111-S119, 1992
76. Kiberd BA, Jindal KK: Screening to prevent renal failure in insulin dependent diabetic patients: An economic evaluation. Br Med J 311: 1595-1599, 1995
77. Rodby RA, Firth LM, Lewis EJ, and the Collaborative Study Group: An economic analysis of captopril in the treatment of diabetic nephropathy. Diabetes Care 19: 1051-1061, 1996
78. The Diabetes Control and Complications Trial Research Group: Effect of intensive therapy on the development and progression of diabetic nephropathy in the diabetes control and complications trial. Kidney Int 47: 1703-1720, 1995
79. Ohkubo Y, Kishikawa H, Araki E: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract 28: 103-117, 1995
80. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77: 1925-1930, 1986
81. Munter K, Hergenroder S, Jochims K, Kirchengast M: Individual and combined effects of verapamil or trandolapril on attenuating hypertensive glomerulopathic change in the stroke-prone rat. J Am Soc Nephrol 7: 681-686, 1996
82. Bakris GL, Barnhill BW, Sadler R: Treatment of arterial hypertension in diabetic humans: Importance of therapeutic selection. Kidney Int 41: 912-919, 1992
83. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S: Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 50: 1641-1650, 1996
84. Brown S, Walton C, Crawford P, Backris GL: Comparative renal hemodynamic effects of an ACE-inhibitor or calcium antagonist on progression of diabetic nephropathy in the dog. Kidney Int 43: 1210-1218, 1993
85. Bakris GL, Weir M, De Quattro V, Rosendorff G, McMahon G: Renal hemodynamic and antiproteinuric response to an ACE inhibitor, trandolapril (T), or a calcium channel antagonist, Verapamil (V), alone or in fixed dose combination in patients with diabetic nephropathy: A randomized multicenter study [Abstract]. J Am Soc Nephrol 7: 1546, 1996
86. American Diabetes Association: Diabetic nephropathy. Diabetes Care 21[Suppl 1]: S50-S53, 1998